In multiple myeloma (MM), the combination of ABT-737 and GSIs leads to BAK and BAX activation and consequently to cytochrome c release, enhancing the synergistic effect of the drugs and suggesting this combination as a potential therapeutic strategy for MM patients. The gene discussed is BAK1; the disease is Miyoshi myopathy.